How big is the Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market?

July 2022: Glenmark Pharmaceuticals Limited announced the launch of sitagliptin and its fixed-dose combinations for adults with Type 2 diabetes in India. Glenmark introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price.
May 2022: As Januvia/Janumet (sitagliptin), a Merck & Co drug, nears patent expiry, India's drug price regulator National Pharmaceutical Pricing Authority (NPPA), fixed the prices of fixed-dose combinations of several anti-diabetic drugs with a 50% reduction on the patented component.

The Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market size is expected to reach USD 4.30 billion in 2024 and grow at a CAGR of 3.80% to reach USD 5.18 billion by 2029. Read More

What is the current Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market size?

In 2024, the Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market size is expected to reach USD 4.30 billion. Read More

Who are the key players in Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market?

AstraZeneca, Eli Lilly and Company, Merck and Co., Novartis AG and Bristol-Myers Squibb are the major companies operating in the Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Read More

What years does this Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market cover, and what was the market size in 2023?

In 2023, the Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market size was estimated at USD 4.14 billion. The report covers the Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More